Home › Compare › SCNLF vs NNN

SCNLF vs NNN: Dividend Comparison 2026

SCNLF yields 1373.63% · NNN yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCNLF wins by $315919182.76M in total portfolio value
10 years
SCNLF
SCNLF
● Live price
1373.63%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$315919182.78M
Annual income
$276,344,297,604,930.75
Full SCNLF calculator →
NNN
NNN REIT Inc.
● Live price
5.28%
Share price
$42.80
Annual div
$2.26
5Y div CAGR
2.8%
Payout ratio
71%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$1,147.75
Full NNN calculator →

Portfolio growth — SCNLF vs NNN

📍 SCNLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCNLFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCNLF + NNN cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
SCNLF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCNLF
Annual income on $10K today (after 15% tax)
$116,758.24/yr
After 10yr DRIP, annual income (after tax)
$234,892,652,964,191.12/yr
NNN
Annual income on $10K today (after 15% tax)
$448.83/yr
After 10yr DRIP, annual income (after tax)
$975.59/yr
At 15% tax rate, SCNLF beats the other by $234,892,652,963,215.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCNLF + NNN for your $10,000?

SCNLF: 50%NNN: 50%
100% NNN50/50100% SCNLF
Portfolio after 10yr
$157959591.40M
Annual income
$138,172,148,803,039.25/yr
Blended yield
87.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

SCNLF
No analyst data
Altman Z
-12.0
Piotroski
2/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+5.0% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCNLF buys
0
NNN buys
0
No recent congressional trades found for SCNLF or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCNLFNNN
Forward yield1373.63% ✓5.28%
Annual dividend / share$2.00$2.26 ✓
Payout ratio50% ✓71%
1-year div growth0%2.7% ✓
5-year div CAGR0%2.8% ✓
Portfolio after 10y$315919182.78M ✓$19.7K
Annual income after 10y$276,344,297,604,930.75 ✓$1,147.75
Total dividends collected$313011682.66M ✓$8.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: SCNLF vs NNN ($10,000, DRIP)

YearSCNLF PortfolioSCNLF Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$148,063$137,362.64$10,663$542.82+$137.4K → SCNLF
2$2,059,200$1,900,773.30$11,379$587.95+$2.05M → SCNLF
3$26,909,187$24,705,842.24$12,153$637.35+$26.90M → SCNLF
4$330,522,388$301,729,558.78$12,990$691.46+$330.51M → SCNLF
5$3,817,312,082$3,463,653,126.46$13,897$750.78+$3817.30M → SCNLF
6$41,470,385,979$37,385,862,050.80$14,879$815.88+$41470.37M → SCNLF
7$423,953,934,089$379,580,621,092.34$15,945$887.39+$423953.92M → SCNLF
8$4,080,240,641,140$3,626,609,931,664.44$17,102$965.99+$4080240.62M → SCNLF
9$36,985,873,996,458$32,620,016,510,437.74$18,360$1,052.49+$36985873.98M → SCNLF
10$315,919,182,781,141$276,344,297,604,930.75$19,728$1,147.75+$315919182.76M → SCNLF

SCNLF vs NNN: Complete Analysis 2026

SCNLF — Stock

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Full SCNLF Calculator →

NNN — REIT

NNN REIT (formerly National Retail Properties) is a Dividend King with 34+ consecutive years of dividend increases — one of only three REITs to achieve this status. Focuses on single-tenant properties with long-term net leases to operators in necessity-based retail sectors.

Full NNN Calculator →
📬

Get this SCNLF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCNLF vs SCHDSCNLF vs JEPISCNLF vs OSCNLF vs KOSCNLF vs MAINSCNLF vs ADCSCNLF vs EPRTSCNLF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.